Objectives. To study the relationship of 25(OH)D 3 level with disease activity, vascular risk factors and atherosclerosis in SLE.
Introduction
Vitamin D is a group of fat-soluble secosteroids that exist in either vitamin D2 (ergocalciferol) or D3 (cholecalciferol). Vitamin D3 is mainly synthesized in the skin after ultraviolet light exposure [1] and is converted by the liver to 25-hydroxycholecalciferol (calcidiol) , which is further metabolized to the biologically active 1,25(OH) 2 D 3 (calcitriol) by the kidneys and the immune system [2] . Calcitriol mediates its effects through the vitamin D receptors (VDRs) located at the nuclei of the target tissues, which maintains homeostasis of calcium level and BMC [3] .
The presence of VDRs on immune cells suggests that vitamin D also has modulating effects on both the innate and adaptive immunity [2] . In vitro studies have shown that vitamin D enhances chemotaxis and phagocytosis of macrophages, inhibits the production of IL-17 by T cells, reduces proliferation and differentiation of B cells, leading to a decrease in immunoglobulin production [46] . Moreover, animal studies demonstrate that VDR agonists induce the production of regulatory and NK T cells that inhibit the Th1 response [7] . Calcitriol has also been shown to inhibit the development of dendritic cells and induce their apoptosis, leading to suppression of dendritic cell-dependent T-cell activation [8] .
SLE is a multi-systemic autoimmune disease. Many of the observed immunological aberrations such as defective T-cell regulation of B-cell activity, over-production of autoantibodies and reduced phagocytic clearance of immune complexes and apoptotic bodies [9] are opposite to the actions of calcitriol. Low levels of vitamin D have been hypothesized to be a risk factor for the development of rheumatic disorders and persistence of disease activity [10] . A number of studies have revealed a high prevalence of vitamin D insufficiency and deficiency in patients with SLE [1121] . However, the association between 25(OH)D 3 level and SLE disease activity is controversial. While some studies reported a reciprocal relationship [11, 12, 14, 16, 17] , others failed to show a link [13, 15, 18, 20] . Moreover, data on correlation between vitamin D levels and disease activity in different systems were unavailable.
Patients with SLE are prone to accelerated atherosclerosis, in part because of the increased prevalence of traditional risk factors and chronic elevation of atherogenic cytokines [22] . In a recent study, hypovitaminosis D in SLE patients was shown to be significantly associated with increased fasting glucose level, but not with other vascular risk factors [16] . Vitamin D level in Asian patients with SLE has not been adequately studied. We undertook this cross-sectional study to evaluate the relationship between 25(OH)D 3 level and disease activity in Chinese patients with SLE. We also examined the link between 25(OH)D 3 level, traditional vascular risk factors and atherosclerosis.
Patients and methods

Study population
Between April and June 2008, consecutive patients who fulfilled four or more of the ACR criteria for the classification of SLE [23] were recruited from our lupus clinics and hospital admissions. Blood was taken for the assay of 25(OH)D 3 . Patients with at least one traditional atherosclerotic risk factor but no ischaemic symptoms and a previous history of arterial thromboembolism were selected for screening of atherosclerosis at the coronary or the carotid arteries. Clinical activity of SLE was assessed by standard tools and regression analyses were made between 25(OH)D 3 levels and disease activity scores in different organ systems. The frequency of traditional vascular risk factors was compared between subjects with and without vitamin D deficiency. Levels of 25(OH)D 3 were also compared between patients with and without subclinical atherosclerosis. This study was approved by the Ethics Committee of Tuen Mun Hospital and informed consent was obtained from the participants.
Assessment of SLE activity and damage
Disease activity of SLE was assessed by the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI (SS), a validated instrument employed in the SELENA trials [24] . The physician's global assessment (PGA) of disease activity of SLE (Score 03) was also performed by the attending rheumatologists to grade their impression of the disease activity of the patients [25] . SS and PGA scores were obtained from all the patients at the time of venepuncture. Flares of SLE were also assessed by the SELENA flare instrument [24] , according to the clinical status of the patients at the time of blood taking with respect to that at the latest clinic visit.
Screening for atherosclerosis
Atherosclerosis at three sites of the carotid arteries on both sides (common carotid, carotid bulb and internal carotid) was measured by B-mode US (Vivid 7 Dimension, GE Healthcare, USA) using high frequency 10 MHz linear array transducers. Carotid intimamedia thickness (IMT) was defined as the distance between the lumenintima interface and the mediaadventitia interface, which corresponded to the inner and outer echogenic lines seen on the B-mode US image. An IMT of 50.8 mm (population mean + 2 S.D.s) was considered to be abnormal based on a previous study in healthy individuals in our locality [26] .
Atherosclerosis of the coronary arteries was studied by a Multi-Detector CT (MDCT) scanner (BrillianceTM 16, Philips Medical Systems, Best, The Netherlands). During a single breath hold, scanning was performed from the level of carina to below the base of the heart. Quantification of coronary calcium was performed on a workstation with software for calcium scoring (Heartbeat-CS, Extended Brilliance Workspace, Philips Medical Systems, Best, The Netherlands). Calcified lesions in the left main, left anterior descending, left circumflex and right coronary arteries were identified. The sum of the scores for all lesions in all coronary arteries yielded the total Agatston score. An Agatston score of 51 was considered to be abnormal. The personnel who performed the US and MDCT scan examinations were blinded for the clinical information of the patients.
Assay of 25(OH)D 3 and definition of insufficiency
Levels of 25(OH)D 3 were measured in serum samples, in duplicate, using a commercial ELISA kit according to the manufacturer's instructions (Immunodiagnostic Systems Inc., Fountain Hills, AZ, USA). All blood samples were collected at 9 a.m. Vitamin D insufficiency was defined as a 25(OH)D 3 level of <30 ng/ml, whereas vitamin deficiency was defined as a level of <15 ng/ml.
Statistical analyses
Unless otherwise stated, values in this study were expressed as mean (S.D.). Continuous variables between two groups were compared by the independent Student's t-test. Categorical variables were compared by the chi-square test. Fisher's exact test was used when the frequency was <5. Correlation between www.rheumatology.oxfordjournals.org SLEDAI scores in different organs and 25(OH)D 3 levels was studied by linear regression, with adjustment for age, sex, SLE duration, mean daily duration of sunshine in the month when blood samples were collected, current use of calcium, rocaltrol, duration of glucocorticoid treatment and whether other immunosuppressive agents such as HCQ, CYC, MMF, AZA or the calcineurin inhibitors were ever used. The standardized regression coefficients (b) and P-values were calculated for the SLEDAI scores in each system. Statistical significance was defined as a two-tailed P-value of <0.05. All statistical analyses were performed using the SPSS program, version 15.0 (SPSS, Chicago, IL, USA, 2002) for Windows Vista.
Results
Clinical characteristics of SLE patients
Two hundred and ninety SLE patients were studied. There were 274 (94%) women and the mean (S.D.) age was 38.9 (13.1) years. The mean (S.D.) disease duration was 7.7 (6.7) years. Table 1 summarizes the cumulative clinical manifestations and autoantibodies of our patients at the time of venepuncture. Two hundred and twenty-five (78%) patients had clinical or serological lupus activity (SLEDAI 5 1) and 37 (13%) had a SLEDAI score of 512.
The median SLEDAI score was 4 [interquartile range (IQR)
26]. The median PGA score was 0.5 (IQR 012). The proportion of patients with active disease in different systems was as follows: renal disease (22%), dermatological disease (16%), haematological disease (14%), musculoskeletal disease (9%), serositis (3%) and documented vasculitis (3%). Two hundred and ten (72%) patients had elevated anti-dsDNA titre or suppressed complement levels.
25(OH)D 3 level and correlation with disease activity
The mean (S.D.) 25(OH)D 3 level of all the patients studied was 19.1 (6.2) ng/ml. Two hundred and seventy-seven (96%) patients had vitamin D insufficiency (<30 ng/ml) and 77 (27%) patients had vitamin D deficiency (<15 ng/ml). Table 2 shows the results of linear regression analysis for the correlation between 25(OH)D 3 levels and SLEDAI score in different systems after adjustment for age, sex, SLE duration, mean duration of sunshine in the month when the blood samples were collected, current use of calcium and rocaltrol and immunosuppressive medications. Levels of 25(OH)D 3 correlated significantly and inversely with the total SLEDAI scores (b À0.19; P = 0.003) and PGA scores (b À0.20; P = 0.003). SLEDAI scores due to active renal, musculoskeletal and haematological manifestations also correlated inversely with 25(OH)D 3 levels, with the largest regression coefficient being renal disease (b À0.18; P = 0.004). Figure 1a shows the 25(OH)D 3 levels in subjects with active disease in different systems compared with those without. Patients with active renal, musculoskeletal, skin, serosal and haematological disease had significantly lower mean levels of 25(OH)D 3 than those without activity in these systems. Eighty-one (28%) patients had disease flares according to the SELENA flare instrument at the time of venepuncture-62 (21%) had mild/moderate flares and 45 (16%) had severe flares. 25(OH)D 3 levels were significantly lower in patients who had disease flares than those without (Fig. 1a) . Figure 1b shows the 25(OH)D 3 levels of patients with regard to the use of various medications. Current use of calcium and rocaltrol was associated with significantly higher levels of 25(OH)D 3 . However, there was no effect of the use of immunosuppressive agents on the levels of 25(OH)D 3 .
Traditional risk factors, atherosclerosis and 25(OH)D 3 level Table 3 compares the prevalence of traditional atherosclerotic risk factors between patients with (<15 ng/ml) and without (515 ng/ml) deficiency of 25(OH)D 3 . Subjects with vitamin D deficiency were younger (P = 0.06) and less likely to be post-menopausal (P = 0.02); and the levels of low-density lipoprotein (LDL) cholesterol (P = 0.02) and triglyceride (P = 0.007) were significantly higher than in those without vitamin D deficiency. Moreover, vitamin D-deficient patients had a significantly lower level of HDL cholesterol (P = 0.004); and higher ratios of total/HDL cholesterol www.rheumatology.oxfordjournals.org P = 0.01). Patients with vitamin D deficiency were also more likely to be positive for aPLs (57 vs 39%; P = 0.007). However, there was no significant difference in the mean daily duration of sunshine in the month when blood samples were collected between patients with and without vitamin D deficiency. One hundred and thirty-two SLE patients consented to screening for atherosclerosis, with 58 (44%) patients showing evidence of abnormal carotid IMT or coronary calcification score. Table 4 shows the 25(OH)D 3 level and atherosclerotic risk factors in patients with and without subclinical atherosclerosis. Patients with atherosclerosis were significantly older and more likely to be post-menopausal, and had significantly higher BMI and serum triglyceride levels. The frequency of other traditional risk factors was similar between the two [11, 12, 14, 16, 17] but others failed to show a link [3, 15, 18, 20] . While the discrepancy is related to many factors such as sample size, seasonal variation in vitamin D levels, the proportion of studied subjects with high disease activity and the distribution of disease activity in different organs, a recent large multi-centred study in Europe and the Middle East that involved 378 SLE patients demonstrated a clear inverse relationship between disease activity and 25(OH)D 3 levels [11] . This is in accordance with our results, which also showed a reciprocal relationship between 25(OH)D 3 level and SLEDAI score, which was independent of age, sex, disease duration, sunshine duration and the use of vitamin D supplement and immunosuppressive agents. In addition, we showed that the significant relationship between disease activity scores and vitamin D level was confined to active renal, musculoskeletal and haematological manifestations of SLE. Although patients with active dermatological disease had significantly lower 25(OH)D 3 level, this was not unique to dermatological manifestations and no correlation between vitamin D level and mucocutaneous SLEDAI subscores could be demonstrated. This could be partially explained by the universal advice for sun-screening to our patients regardless of dermatological lesions.
Although the associations between vitamin D levels and SLE activity of some systems were statistically significant, the correlations were not strong, indicating that there are still many yet unknown exogenous or endogenous factors in addition to low vitamin D level that are related to disease activity in SLE. As we did not have baseline levels of 25(OH)D 3 in our patients before study entry, we are unable to show that patients with lower vitamin D levels are more prone to the development of more serious disease manifestations or more frequent flares. However, patients with new disease flares, as defined by the SELENA flare instrument, had significantly lower levels of 25(OH)D 3 compared with those without. This observation provides some evidence to indicate that 25(OH)D 3 level may be a marker for disease activity in SLE. We have recently performed a longitudinal study in an Ohio-based lupus cohort (the Ohio SLE Study), and found an association between abnormally large seasonal decreases in circulating 25(OH)D 3 levels and the onset of lupus flare [27] . Together, these data support our postulate that low vitamin D level in patients with established SLE may be a factor for perpetuation of disease activity or for increased risk of disease flares. However, statistical association does not differentiate between cause and effect of two variables. It is formally possible that SLE patients with more active disease are prone to vitamin D deficiency as a result of avoidance of sunshine and outdoor physical activities, use of photoprotection, renal insufficiency, chronic use of medications that alter vitamin D metabolism or reduce its absorption such as gluocorticoids, anti-malarials and anti-convulsants, as well as the presence of anti-vitamin D antibodies, which may enhance the plasma clearance of vitamin D [28, 29] . Placebo-controlled trials of the efficacy of vitamin D supplement in reducing SLE disease activity on top of background therapies may help to clarify the role of vitamin D in SLE patients.
There is increasing evidence that vitamin D deficiency is linked to cardiovascular disease. Observational studies have suggested an association between low 25(OH)D 3 level and stroke, myocardial infarction, diabetes mellitus, hypertensive heart disease, obesity and dyslipidaemia [3033] . The suggested mechanisms for the deleterious effects of vitamin D deficiency on the cardiovascular system include decreased renin activity, increased peripheral resistance to insulin, reduced immuno-modulating effects of cytokines and hormones such as TNF-a, IL-10 and PTH, altered vascular endothelial functions and increased coronary artery calcification [34] . In our study, we were able to show that low levels of vitamin D were associated with younger age, pre-menopausal status and higher atherogenic lipoprotein indices (total/HDL and LDL/ HDL ratios). The relationship between vitamin D deficiency and dysplipidaemia is consistent with that reported in non-SLE general population studies [33] . However, the increased prevalence of other traditional risk factors such as diabetes mellitus and hypertension in vitamin D-deficient SLE patients could not be demonstrated in our study, probably related to the small number of patients having these risk factors.
Hypovitaminosis D has been linked to coronary and carotid atherosclerosis in the general population [35, 36] .
www.rheumatology.oxfordjournals.org However, we were not able to show that patients with subclinical atherosclerosis in either the coronary or carotid vessels had lower vitamin D3 levels. Atherosclerosis was related to older age, menopause, higher BMI and elevated triglyceride level. Our results are in line with those reported by Wu et al. [16] who also failed to show an association between cardiovascular risk factors (except increased fasting glucose) and low vitamin D level in a multivariate model.
The strength of the current study is the relatively large sample size for the correlation studies between 25(OH)D 3 levels and disease activity of SLE in different systems. Due to the limitation in resources, we could not perform universal screening of subclinical atherosclerosis for all patients. The smaller number of patients recruited for the atherosclerosis study and the omission of patients without vascular risk factors might have contributed to the negative association between atherosclerosis and vitamin D levels. In summary, this study shows an inverse relationship between 25(OH)D 3 level and disease activity in SLE. Although lower level of vitamin D is associated with higher atherogenic lipoprotein ratios, there is no 
